2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106927
    Bay Y5959 146136-94-9 98%
    Bay Y5959 is a potent calcium channel agonist. Bay Y5959 binds to the DHP receptor in a voltage-dependent manner increases both the mean open time and the mean closed time of the Ca-channel. Bay Y5959 has the potential for the research of congestive heart failure, arrhythmic.
    Bay Y5959
  • HY-107023
    AZD 9684 775274-06-1 98%
    AZD 9684 is a TAFIa inhibitor. AZD 9684 is applicable to research related to thrombosis and pulmonary embolism.
    AZD 9684
  • HY-107036
    BMS-394136 343246-73-1 98%
    BMS-394136 (compound 1) is a potent inhibitor of Kv 1.5, with an IC50 of 0.05 μM. BMS-394136 is a selective IKur inhibitor. BMS-394136 dose-dependently prolongs atrial effective refractory period (AERP) and action potential duration (APD) without effecting ventricular effective refractory period (VERP). BMS-394136 can be used for acute atrial ischemia research.
    BMS-394136
  • HY-107186
    EO-122 23581-62-6 98%
    EO-122 is a potent antagonist of calcium channel and sodium channel potentially for the research of arrhythmia.
    EO-122
  • HY-10787R
    Ximelagatran (Standard) 192939-46-1 98%
    Ximelagatran (Standard) is the analytical standard of Ximelagatran (HY-10787). This product is intended for research and analytical applications. Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcoKinetics and pharmacodynamics.
    Ximelagatran (Standard)
  • HY-108163
    SB-237376 free base 179258-59-4 98%
    SB-237376 (free base) is a potassium and calcium channel blocker. SB-237376 (free base) can inhibit the rapidly activating delayed rectifier potassium current I(Kr) (IC50 is 0.42 μM), and at high concentrations, it blocks the L-type calcium current I(Ca,L). In the rabbit ventricular model, SB-237376 (free base) can induce early afterdepolarizations (EADs) at a concentration of 3 µM. Compared to other IKr inhibitors such as dl-sotalol, SB-237376 has a lower proarrhythmic risk. SB-237376 (free base) holds potential for research in the field of arrhythmia-related diseases.
    SB-237376 free base
  • HY-108247
    Guanethidine sesquisulfate 60-02-6 98%
    Guanethidine sesquisulfate, an antihypertensive agent, is an adrenergic neurone blocking agent. Guanethidine sesquisulfate enters noradrenergic nerve terminals by the neuronal amine carrier.
    Guanethidine sesquisulfate
  • HY-10835R
    DG-041 (Standard) 861238-35-9
    DG-041 (Standard) is the analytical standard of DG-041 (HY-10835). This product is intended for research and analytical applications. DG-041 is a potent, high affinity and selective EP3 receptor antagonist with IC50s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits PGE2 facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier.
    DG-041 (Standard)
  • HY-108775
    Sodium thiosulfate (98%) 7772-98-7 98%
    Sodium thiosulfate (Sodium hyposulfite) is an antioxidant. Sodium thiosulfate inhibits the expression of p-GSK-3β and β-catenin proteins, reduces IL-1β, COX-2, and Iba-1, and inhibits NFκB activation. Sodium thiosulfate promotes angiogenesis, inhibits inflammation, and improves acute lung injury. Sodium thiosulfate also exhibits anti-cancer activity against melanoma. Sodium thiosulfate also exerts renal protective effects. Sodium thiosulfate can be used in the research of osteoarthritis, brain inflammation, cancer (such as breast cancer, melanoma), and kidney disease.
    Sodium thiosulfate (98%)
  • HY-108936
    QCC374 1356331-63-9 98%
    QCC374 is a selective agonist of IP.
    QCC374
  • HY-108981
    CERM11956 97631-49-7 98%
    CERM11956 is a potent anti-ischaemic agent. CERM11956 is a derivative of bepridil(HY-16952).
    CERM11956
  • HY-10913S
    Danegaptide-d5 98%
    Danegaptide-d5 (GAP-134-d5) is deuterium labeled Danegaptide. Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect.
    Danegaptide-d5
  • HY-10915R
    LUF6096 (Standard) 1116652-18-6 98%
    LUF6096 (Standard) is the analytical standard of LUF6096 (HY-10915). This product is intended for research and analytical applications. LUF6096, a potent allosteric enhancer of the adenosine A3 receptor, is able to allosterically enhance agonist binding. LUF6096 shows low orthosteric affinity for any of the adenosine receptors. LUF6096 shows protective effects in myocardial ischemia/reperfusion injury.
    LUF6096 (Standard)
  • HY-109992
    LY 186126 100644-00-6 98%
    LY 186126 a Indolidan analog, is a phosphodiesterase (PDE) inhibitor. LY 186126 binds to cardiac sarcoplasmic reticulum PDE with high affinity, with a Kd of 5.6 nM.
    LY 186126
  • HY-110038
    FTI-277 TFA 1217447-06-7 98%
    FTI-277 TFA is a farnesyltransferase (FTase) inhibitor. FTI-277 TFA inhibits Ras farnesylation, blocks the phosphorylation of downstream ERK1/2 and mTOR, and reduces membrane-bound active N-ras protein. FTI-277 TFA activates caspase 3, upregulates Bim expression, induces cell apoptosis, suppresses regulatory T cell expansion, enhances macrophage phagocytosis, and improves bacterial clearance. FTI-277 TFA activates the PI3K/Akt signaling pathway, inhibits osteoblast differentiation, and reduces the proliferation ability of neuroblastoma cells. FTI-277 TFA can be used in research related to head and neck squamous cell carcinoma, neuroblastoma, sepsis, and vascular calcification.
    FTI-277 TFA
  • HY-110043
    (±)-Clopidogrel hydrochloride 130209-90-4
    (±)-Clopidogrel hydrochloride is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel hydrochloride inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors.
    (±)-Clopidogrel hydrochloride
  • HY-110102
    Atiprimod hydrochloride 130065-61-1 98%
    Atiprimod (Azaspirane) hydrochloride is a STAT3 inhibitor with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of IL-6 and VEGF by inhibiting the phosphorylation of signal transducer and activator of STAT3. Atiprimod blocks the JAK-STAT signaling pathway by inhibiting the phosphorylation of JAK2 and JAK3. Atiprimod also inhibits cell proliferation, induces cell cycle arrest, and induces autophagy and apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB. Atiprimod shows great anti-tumor activities in tumor xenograft mouse models. Atiprimod can be used for the study of pituitary adenoma, breast cancer, multiple myeloma and acute myeloid leukemia (AML).
    Atiprimod hydrochloride
  • HY-110169
    (E/Z)-3PO 13309-08-5 99.86%
    (E/Z)-3PO is a potent PFKFB3 inhibitor. (E/Z)-3PO can inhibit the glycolysis process, reduce the extracellular acidification rate, and inhibit the capillary tube formation, migration of endothelial cells, and the formation of aortic sprouts, thereby suppressing angiogenesis. (E/Z)-3PO is promising for research of diseases such as cancer, acute lung injury, pulmonary fibrosis, and atherosclerosis.
    (E/Z)-3PO
  • HY-11103R
    Sitaxsentan sodium (Standard) 210421-74-2 98%
    Sitaxsentan (sodium) (Standard) is the analytical standard of Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) (HY-11103). This product is intended for research and analytical applications. Sitaxsentan sodium is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan sodium exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension.
    Sitaxsentan sodium (Standard)
  • HY-111064
    BX 667 937395-08-9 98%
    BX 667 is an orally active reversible P2Y(12) receptor antagonist. BX 667 attenuates thrombosis.
    BX 667
Cat. No. Product Name / Synonyms Application Reactivity